CuraSen Therapeutics, Inc. Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing novel treatments for neurodegenerative diseases, including Parkinson's and Alzheimer's, as well as orphan indications. The company pursues a therapeutic concept aimed at restoring a key functionality to a brain pathway emanating from the locus coeruleus, a region linked to early neurodegenerative pathology. It began evaluating its approach in 2019 by repurposing established drugs, which led to CST-2032 advancing into clinical testing in September 2020. The organization describes its work as developing oral, rapid-onset small molecule therapies for neurodegenerative and psychiatric conditions, underpinned by neuroscience and pharmacology-focused clinical development. In October 2024, CuraSen appointed Kathleen Sereda Glaub as chief executive officer, marking a notable leadership update.